304 related articles for article (PubMed ID: 29301535)
21. Iron Homeostasis and Inflammatory Status in Mice Deficient for the Cystic Fibrosis Transmembrane Regulator.
Deschemin JC; Allouche S; Brouillard F; Vaulont S
PLoS One; 2015; 10(12):e0145685. PubMed ID: 26709821
[TBL] [Abstract][Full Text] [Related]
22. In vivo monitoring of lung inflammation in CFTR-deficient mice.
Stellari F; Bergamini G; Ruscitti F; Sandri A; Ravanetti F; Donofrio G; Boschi F; Villetti G; Sorio C; Assael BM; Melotti P; Lleo MM
J Transl Med; 2016 Jul; 14(1):226. PubMed ID: 27468800
[TBL] [Abstract][Full Text] [Related]
23. Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor.
Reiniger N; Lee MM; Coleman FT; Ray C; Golan DE; Pier GB
Infect Immun; 2007 Apr; 75(4):1598-608. PubMed ID: 17283089
[TBL] [Abstract][Full Text] [Related]
24. Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway.
Eidelman O; Srivastava M; Zhang J; Leighton X; Murtie J; Jozwik C; Jacobson K; Weinstein DL; Metcalf EL; Pollard HB
Mol Med; 2001 Aug; 7(8):523-34. PubMed ID: 11591888
[TBL] [Abstract][Full Text] [Related]
25. Anti-inflammatory effect of miglustat in bronchial epithelial cells.
Dechecchi MC; Nicolis E; Norez C; Bezzerri V; Borgatti M; Mancini I; Rizzotti P; Ribeiro CM; Gambari R; Becq F; Cabrini G
J Cyst Fibros; 2008 Nov; 7(6):555-65. PubMed ID: 18815075
[TBL] [Abstract][Full Text] [Related]
26. Protease inhibitors elicit anti-inflammatory effects in CF mice with Pseudomonas aeruginosa acute lung infection.
Sandri A; Lleo MM; Signoretto C; Boaretti M; Boschi F
Clin Exp Immunol; 2021 Jan; 203(1):87-95. PubMed ID: 32946591
[TBL] [Abstract][Full Text] [Related]
27. Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies.
Belcher CN; Vij N
Curr Mol Med; 2010 Feb; 10(1):82-94. PubMed ID: 20205681
[TBL] [Abstract][Full Text] [Related]
28. Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation.
Ortiz-Muñoz G; Yu MA; Lefrançais E; Mallavia B; Valet C; Tian JJ; Ranucci S; Wang KM; Liu Z; Kwaan N; Dawson D; Kleinhenz ME; Khasawneh FT; Haggie PM; Verkman AS; Looney MR
J Clin Invest; 2020 Apr; 130(4):2041-2053. PubMed ID: 31961827
[TBL] [Abstract][Full Text] [Related]
29. Proresolving Action of Docosahexaenoic Acid Monoglyceride in Lung Inflammatory Models Related to Cystic Fibrosis.
Morin C; Cantin AM; Rousseau É; Sirois M; Sirois C; Rizcallah E; Fortin S
Am J Respir Cell Mol Biol; 2015 Oct; 53(4):574-83. PubMed ID: 25781052
[TBL] [Abstract][Full Text] [Related]
30. The histone deacetylase inhibitor trichostatin A suppresses murine innate allergic inflammation by blocking group 2 innate lymphoid cell (ILC2) activation.
Toki S; Goleniewska K; Reiss S; Zhou W; Newcomb DC; Bloodworth MH; Stier MT; Boyd KL; Polosukhin VV; Subramaniam S; Peebles RS
Thorax; 2016 Jul; 71(7):633-45. PubMed ID: 27071418
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.
Hsu D; Taylor P; Fletcher D; van Heeckeren R; Eastman J; van Heeckeren A; Davis P; Chmiel JF; Pearlman E; Bonfield TL
Infect Immun; 2016 Sep; 84(9):2410-21. PubMed ID: 27271746
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS.
Halili MA; Andrews MR; Labzin LI; Schroder K; Matthias G; Cao C; Lovelace E; Reid RC; Le GT; Hume DA; Irvine KM; Matthias P; Fairlie DP; Sweet MJ
J Leukoc Biol; 2010 Jun; 87(6):1103-14. PubMed ID: 20200406
[TBL] [Abstract][Full Text] [Related]
33. Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs.
Keiser NW; Birket SE; Evans IA; Tyler SR; Crooke AK; Sun X; Zhou W; Nellis JR; Stroebele EK; Chu KK; Tearney GJ; Stevens MJ; Harris JK; Rowe SM; Engelhardt JF
Am J Respir Cell Mol Biol; 2015 Jun; 52(6):683-94. PubMed ID: 25317669
[TBL] [Abstract][Full Text] [Related]
34. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
[TBL] [Abstract][Full Text] [Related]
35. Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema.
Bodas M; Min T; Mazur S; Vij N
J Immunol; 2011 Jan; 186(1):602-13. PubMed ID: 21135173
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Cebotaru L; Liu Q; Yanda MK; Boinot C; Outeda P; Huso DL; Watnick T; Guggino WB; Cebotaru V
Kidney Int; 2016 Jul; 90(1):90-9. PubMed ID: 27165822
[TBL] [Abstract][Full Text] [Related]
37. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections.
Pier GB
Proc Natl Acad Sci U S A; 2000 Aug; 97(16):8822-8. PubMed ID: 10922041
[TBL] [Abstract][Full Text] [Related]
38. The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential.
Bodas M; Vij N
Discov Med; 2010 Apr; 9(47):346-56. PubMed ID: 20423679
[TBL] [Abstract][Full Text] [Related]
39. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
Leoni F; Zaliani A; Bertolini G; Porro G; Pagani P; Pozzi P; Donà G; Fossati G; Sozzani S; Azam T; Bufler P; Fantuzzi G; Goncharov I; Kim SH; Pomerantz BJ; Reznikov LL; Siegmund B; Dinarello CA; Mascagni P
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2995-3000. PubMed ID: 11867742
[TBL] [Abstract][Full Text] [Related]
40. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.
Reilly CM; Mishra N; Miller JM; Joshi D; Ruiz P; Richon VM; Marks PA; Gilkeson GS
J Immunol; 2004 Sep; 173(6):4171-8. PubMed ID: 15356168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
